statistiche ricercatore

Continente	#
NA - Nord America	1.095
AS - Asia	752
EU - Europa	486
SA - Sud America	99
Continente sconosciuto - Info sul continente non disponibili	45
AF - Africa	20
OC - Oceania	3
Totale	2.500

Nazione	#
US - Stati Uniti d'America	1.047
SG - Singapore	227
VN - Vietnam	184
IT - Italia	157
CN - Cina	141
HK - Hong Kong	79
BR - Brasile	75
RU - Federazione Russa	72
DE - Germania	57
IE - Irlanda	42
GB - Regno Unito	34
SE - Svezia	32
CA - Canada	29
FR - Francia	29
IN - India	20
ID - Indonesia	19
BD - Bangladesh	15
TR - Turchia	15
FI - Finlandia	13
KR - Corea	12
PL - Polonia	12
AR - Argentina	11
ZA - Sudafrica	9
MX - Messico	8
ES - Italia	7
JP - Giappone	7
UA - Ucraina	7
IQ - Iraq	6
UZ - Uzbekistan	6
AT - Austria	5
CR - Costa Rica	5
PK - Pakistan	5
VE - Venezuela	5
CH - Svizzera	4
NL - Olanda	4
PH - Filippine	4
CO - Colombia	3
EC - Ecuador	3
EU - Europa	3
KE - Kenya	3
LT - Lituania	3
SA - Arabia Saudita	3
TN - Tunisia	3
AE - Emirati Arabi Uniti	2
AU - Australia	2
DK - Danimarca	2
JM - Giamaica	2
MA - Marocco	2
PE - Perù	2
AO - Angola	1
AZ - Azerbaigian	1
BE - Belgio	1
BH - Bahrain	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
EG - Egitto	1
HN - Honduras	1
HR - Croazia	1
JO - Giordania	1
KG - Kirghizistan	1
KW - Kuwait	1
MK - Macedonia	1
MM - Myanmar	1
MU - Mauritius	1
NI - Nicaragua	1
NZ - Nuova Zelanda	1
PT - Portogallo	1
RO - Romania	1
TJ - Tagikistan	1
TT - Trinidad e Tobago	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	2.459

Nome	#
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization	411
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy	389
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies	370
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy	338
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia	276
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706)	261
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas	234
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi	221
Totale	2.500

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	23	0	0	0	3	1	5	2	2	1	1	3	5
2022/2023	101	6	27	10	3	11	12	4	2	5	1	10	10
2023/2024	186	5	8	20	9	30	45	30	2	19	2	2	14
2024/2025	538	10	33	25	21	33	29	38	9	42	74	50	174
2025/2026	1.110	132	50	75	174	126	60	188	46	75	91	45	48
2026/2027	163	25	34	93	11	0	0	0	0	0	0	0	0
Totale													2.500

Bicocca Open Archive